Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F

Journal of Leukocyte Biology

Volumn 85, Issue 6, 2009, Pages 957-965

  Gery, Sigal ^a,c   Cao, Qi ^a   Gueller, Saskia ^a   Xing, Hongtao ^a   Tefferi, Ayalew ^b   Koeffler, H Phillip ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MAYO CLINIC   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Cancer; Cell lines; Protein kinases phosphatases; Signaling cascade

Indexed keywords

ENZYME INHIBITOR; ERYTHROPOIETIN RECEPTOR; JAK2V617F PROTEIN; JANUS KINASE 2; LNK PROTEIN; PLECKSTRIN; PROTEIN DERIVATIVE; PROTEIN SH2; UNCLASSIFIED DRUG; JAK2 PROTEIN, HUMAN; JAK2 PROTEIN, MOUSE; LNK PROTEIN, HUMAN; LNK PROTEIN, MOUSE; MUTANT PROTEIN; PHENYLALANINE; PROTEIN; VALINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASSAY; BONE MARROW CELL; CD34 SELECTION; CELL TRANSFORMATION; CONTROLLED STUDY; DOWN REGULATION; HEMATOPOIETIC CELL; HUMAN; MOUSE; MUTANT; MUTATION; MYELOPROLIFERATIVE DISORDER; NEGATIVE FEEDBACK; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; WILD TYPE; AMINO ACID SUBSTITUTION; ANIMAL; CELL LINE; CELL PROLIFERATION; CHEMISTRY; CYTOLOGY; DRUG ANTAGONISM; ENZYME ACTIVATION; ENZYMOLOGY; GENETICS; HEMATOPOIETIC SYSTEM; METABOLISM; PROTEIN BINDING; PROTEIN TERTIARY STRUCTURE;

MURINAE;

AMINO ACID SUBSTITUTION; ANIMALS; CELL LINE, TRANSFORMED; CELL PROLIFERATION; ENZYME ACTIVATION; HEMATOPOIETIC SYSTEM; HUMANS; JANUS KINASE 2; MICE; MUTANT PROTEINS; MYELOID CELLS; MYELOPROLIFERATIVE DISORDERS; PHENYLALANINE; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; PROTEINS; VALINE;

EID: 67149083222     PISSN: 07415400     EISSN: None     Source Type: Journal    
DOI: 10.1189/jlb.0908575     Document Type: Article

References (48)

1. Parganas, E., Wang, D., Stravopodis, D., Topham, D. J., Marine, J. C., Teglund, S., Vanin, E. F., Bodner, S., Colamonici, O. R., van Deursen, J. M., Grosveld, G., Ihle, J. N. (1998) Jak2 is essential for signaling through a variety of cytokine receptors. Cell 93, 385-395. (Pubitemid 28232083)
2. Campbell, P. J., Green, A. R. (2006) The myeloproliferative disorders. N. Engl. J. Med. 355, 2452-2466.
3. Levine, R. L., Pardanani, A., Tefferi, A., Gilliland, D. G. (2007) Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat. Rev. Cancer 7, 673-683. (Pubitemid 47327415)
4. Baxter, E. J., Scott, L. M., Campbell, P. J., East, C., Fourouclas, N., Swanton, S., Vassiliou, G. S., Bench, A. J., Boyd, E. M., Curtin, N., Scott, M. A., Erber, W. N., Green, A. R. (2005) Cancer Genome Project Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365, 1054-1061. (Pubitemid 40386783)
5. James, C., Ugo, V., Le Couedic, J. P., Staerk, J., Delhommeau, F., Lacout, C., Garcon, L., Raslova, H., Berger, R., Bennaceur-Griscelli, A., Villeval, J. L., Constantinescu, S. N., Casadevall, N., Vainchenker, W. (2005) A unique clonal JAK2 mutation leading to constitutive signaling causes polycythemia vera. Nature 434, 1144-1148. (Pubitemid 40663494)
6. Levine, R. L., Wadleigh, M., Cools, J., Ebert, B. L., Wernig, G., Huntly, B. J., Boggon, T. J., Wlodarska, I., Clark, J. J., Moore, S., Adelsperger, J., Koo, S., Lee, J. C., Gabriel, S., Mercher, T., D'Andrea, A., Fröhling, S., Döhner, K., Marynen, P., Vandenberghe, P., Mesa, R. A., Tefferi, A., Griffin, J. D., Eck, M. J., Sellers, W. R., Meyerson, M., Golub, T. R., Lee, S. J., Gilliland, D. G. (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7, 387-397. (Pubitemid 40544655)
7. Kralovics, R., Passamonti, F., Buser, A. S., Teo, S. S., Tiedt, R., Passweg, J. R., Tichelli, A., Cazzola, M., Skoda, R. C. (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 352, 1779-1790. (Pubitemid 40570926)
8. Zhao, R., Xing, S., Li, Z., Fu, X., Li, Q., Krantz, S. B., Zhao, Z. J. (2005) Identification of an acquired JAK2 mutation in polycythemia vera. J. Biol. Chem. 280, 22788-22792. (Pubitemid 40853184)
9. Lacout, C., Pisani, D. F., Tulliez, M., Gachelin, F. M., Vainchenker, W., Villeval, J. L. (2006) JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood 108, 1652-1660. (Pubitemid 44316134)
10. Zaleskas, V. M., Krause, D. S., Lazarides, K., Patel, N., Hu, Y., Li, S., Van Etten, R. A. (2006) Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F. PLoS ONE 1, e18.
11. Wernig, G., Mercher, T., Okabe, R., Levine, R. L., Lee, B. H., Gilliland, D. G. (2006) Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 107, 4274-4281. (Pubitemid 43801351)
12. Tiedt, R., Hao-Shen, H., Sobas, M. A., Looser, R., Dirnhofer, S., Schwaller, J., Skoda, R. C. (2008) Ratio of mutant JAK2-V617F to wild type JAK2 determines the MPD phenotypes in transgenic mice. Blood 111, 3931-3940.
13. Lu, X., Levine, R., Tong, W., Wernig, G., Pikman, Y., Zarnegar, S., Gilliland, D. G., Lodish, H. (2005) Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. Proc. Natl. Acad. Sci. USA 102, 18962-18967. (Pubitemid 43049549)
14. Wernig, G., Gonneville, J. R., Crowley, B. J., Rodrigues, M. S., Reddy, M. M., Hudon, H. E., Walz, C., Reiter, A., Podar, K., Royer, Y., Constantinescu, S. N., Tomasson, M. H., Griffin, J. D., Gilliland, D. G., Sattler, M. (2008) The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes. Blood 111, 3751-3759.
15. Lu, X., Huang, L. J., Lodish, H. F. (2008) Dimerization by a cytokine receptor is necessary for constitutive activation of JAK2V617F. J. Biol. Chem. 283, 5258-5266.
16. Ihle, J. N., Gilliland, D. G. (2007) Jak2: normal function and role in hematopoietic disorders. Curr. Opin. Genet. Dev. 17, 8-14.
17. Rudd, C. E. (2001) Lnk adaptor: novel negative regulator of B cell lymphopoiesis. Sci. STKE 2001, PE1.
18. Velazquez, L., Cheng, A. M., Fleming, H. E., Furlonger, C., Vesely, S., Bernstein, A., Paige, C. J., Pawson, T. (2002) Cytokine signaling and hematopoietic homeostasis are disrupted in Lnk-deficient mice. J. Exp. Med. 195, 1599-1611. (Pubitemid 34666073)
19. Takaki, S., Morita, H., Tezuka, Y., Takatsu, K. (2002) Enhanced hematopoiesis by hematopoietic progenitor cells lacking intracellular adaptor protein, Lnk. J. Exp. Med. 195, 151-160. (Pubitemid 34461259)
20. Tong, W., Lodish, H. F. (2004) Lnk inhibits Tpo-mpl signaling and Tpo-mediated megakaryocytopoiesis. J. Exp. Med. 200, 569-580. (Pubitemid 39258306)
21. Tong, W., Zhang, J., Lodish, H. F. (2005) Lnk inhibits erythropoiesis and Epo-dependent JAK2 activation and downstream signaling pathways. Blood 105, 4604-4612. (Pubitemid 40807278)
22. Buza-Vidas, N., Antonchuk, J., Qian, H., Mansson, R., Luc, S., Zandi, S., Anderson, K., Takaki, S., Nygren, J. M., Jensen, C. T., Jacobsen, S. E. (2006) Cytokines regulate postnatal hematopoietic stem cell expansion: opposing roles of thrombopoietin and LNK. Genes Dev. 20, 2018-2023. (Pubitemid 44157453)
23. Takizawa, H., Kubo-Akashi, C., Nobuhisa, I., Kwon, S. M., Iseki, M., Taga, T., Takatsu, K., Takaki, S. (2006) Enhanced engraftment of hematopoietic stem/progenitor cells by the transient inhibition of an adaptor protein, Lnk. Blood 107, 2968-2975.
24. Nobuhisa, I., Takizawa, M., Takaki, S., Inoue, H., Okita, K., Ueno, M., Takatsu, K., Taga, T. (2003) Regulation of hematopoietic development in the aorta-gonad-mesonephros region mediated by Lnk adaptor protein. Mol. Cell. Biol. 23, 8486-8494. (Pubitemid 37433356)
25. Simon, C., Dondi, E., Chaix, A., de Sepulveda, P., Kubiseski, T. J., Varin-Blank, N., Velazquez, L. (2008) Lnk adaptor protein down-regulates specific Kit-induced signaling pathways in primary mast cells. Blood 112, 4039-4047.
26. Gery, S., Gueller, S., Chumakova, K., Kawamata, N., Liu, L., Koeffler, H. P. (2007) Adaptor protein Lnk negatively regulates the mutant MPL, MPLW515L associated with myeloproliferative disorders. Blood 110, 3360-3364. (Pubitemid 350106330)
27. Rui, L., Mathews, L. S., Hotta, K., Gustafson, T. A., Carter-Su, C. (1997) Identification of SH2-Bβ as a substrate of the tyrosine kinase JAK2 involved in growth hormone signaling. Mol. Cell. Biol. 17, 6633-6644. (Pubitemid 27451210)
28. Wakioka, T., Sasaki, A., Mitsui, K., Yokouchi, M., Inoue, A., Komiya, S., Yoshimura, A. (1999) APS, an adaptor protein containing pleckstrin homology (PH) and Src homology-2 (SH2) domains inhibits the JAK-STAT pathway in collaboration with c-Cbl. Leukemia 13, 760-767. (Pubitemid 29243628)
29. Ren, D., Zhou, Y., Morris, D., Li, M., Li, Z., Rui, L. (2007) Neuronal SH2B1 is essential for controlling energy and glucose homeostasis. J. Clin. Invest. 117, 397-406. (Pubitemid 46203968)
30. Maures, T. J., Kurzer, J. H., Carter-Su, C. (2007) SH2B1 (SH2-B) and JAK2: a multifunctional adaptor protein and kinase made for each other. Trends Endocrinol. Metab. 18, 38-45.
31. Morita, S., Kojima, T., Kitamura, T. (2000) Plat-E: an efficient and stable system for transient packaging of retroviruses. Gene Ther. 7, 1063-1066. (Pubitemid 30398356)
32. D'Andrea, A. D., Lodish, H. F., Wong, G. G. (1989) Expression cloning of the murine erythropoietin receptor. Cell 57, 277-285. (Pubitemid 19112366)
33. Kurzer, J. H., Argetsinger, L. S., Zhou, Y. J., Kouadio, J. L., O'Shea, J. J., Carter-Su, C. (2004) Tyrosine 813 is a site of JAK2 autophosphorylation critical for activation of JAK2 by SH2-B β. Mol. Cell. Biol. 24, 4557-4570.
34. Kurzer, J. H., Saharinen, P., Silvennoinen, O., Carter-Su, C. (2006) Binding of SH2-B family members within a potential negative regulatory region maintains JAK2 in an active state. Mol. Cell. Biol. 26, 6381-6394. (Pubitemid 44277879)
35. Bersenev, A., Wu, C., Balcerek, J., Tong, W. (2008) Lnk controls mouse hematopoietic stem cell self-renewal and quiescence through direct interactions with JAK2. J. Clin. Invest. 118, 2832-2844.
36. Rui, L., Gunter, D. R., Herrington, J., Carter-Su, C. (2000) Differential binding to and regulation of JAK2 by the SH2 domain and N-terminal region of SH2-Bβ. Mol. Cell. Biol. 20, 3168-3177. (Pubitemid 30215029)
37. Dhe-Paganon, S., Werner, E. D., Nishi, M., Hansen, L., Chi, Y. I., Shoelson, S. E. (2004) A phenylalanine zipper mediates APS dimerization. Nat. Struct. Mol. Biol. 11, 968-974. (Pubitemid 39315301)
38. Nishi, M., Werner, E. D., Oh, B. C., Frantz, J. D., Dhe-Paganon, S., Hansen, L., Lee, J., Shoelson, S. E. (2005) Kinase activation through dimerization by human SH2-B. Mol. Cell. Biol. 25, 2607-2621. (Pubitemid 40381625)
39. Staerk, J., Kallin, A., Royer, Y., Diaconu, C. C., Dusa, A., Demoulin, J. B., Vainchenker, W., Constantinescu, S. N. (2007) JAK2, the JAK2 V617F mutant and cytokine receptors. Pathol. Biol. (Paris) 55, 88-91.
40. Funakoshi-Tago, M., Pelletier, S., Moritake, H., Parganas, E., Ihle, J. N. (2008) Jak2 FERM domain interaction with the erythropoietin receptor regulates Jak2 kinase activity. Mol. Cell. Biol. 28, 1792-1801.
41. Hu, J., Hubbard, S. R. (2005) Structural characterization of a novel Cbl phosphotyrosine recognition motif in the APS family of adapter proteins. J. Biol. Chem. 280, 18943-18949. (Pubitemid 41379597)
42. Yokouchi, M., Wakioka, T., Sakamoto, H., Yasukawa, H., Ohtsuka, S., Sasaki, A., Ohtsubo, M., Valius, M., Inoue, A., Komiya, S., Yoshimura, A. (1999) APS, an adaptor protein containing PH and SH2 domains, is associated with the PDGF receptor and c-Cbl and inhibits PDGF-induced mitogenesis. Oncogene 18, 759-767. (Pubitemid 29080333)
43. Hu, J., Liu, J., Ghirlando, R., Saltiel, A. R., Hubbard, S. R. (2003) Structural basis for recruitment of the adaptor protein APS to the activated insulin receptor. Mol. Cell 12, 1379-1389. (Pubitemid 38037008)
44. Ahmed, Z., Smith, B. J., Pillay, T. S. (2000) The APS adapter protein couples the insulin receptor to the phosphorylation of c-Cbl and facilitates ligand-stimulated ubiquitination of the insulin receptor. FEBS Lett. 475, 31-34. (Pubitemid 30331072)
45. Wollberg, P., Lennartsson, J., Gottfridsson, E., Yoshimura, A., Rönnstrand, L. (2003) The adapter protein APS associates with the multifunctional docking sites Tyr-568 and Tyr-936 in c-Kit. Biochem. J. 370, 1033-1038. (Pubitemid 36399098)
46. Hookham, M. B., Elliott, J., Suessmuth, Y., Staerk, J., Ward, A. C., Vainchenker, W., Percy, M. J., McMullin, M. F., Constantinescu, S. N., Johnston, J. A. (2007) The myeloproliferative disorder-associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3. Blood 109, 4924-4929. (Pubitemid 46827790)
47. Courtois-Cox, S., Genther Williams, S. M., Reczek, E. E., Johnson, B. W., McGillicuddy, L. T., Johannessen, C. M., Hollstein, P. E., MacCollin, M., Cichowski, K. (2006) A negative feedback signaling network underlies oncogene-induced senescence. Cancer Cell 10, 459-472. (Pubitemid 44872980)
48. Sharma, S. V., Gajowniczek, P., Way, I. P., Lee, D. Y., Jiang, J., Yuza, Y., Classon, M., Haber, D. A., Settleman, J. (2006) A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes. Cancer Cell 10, 425-435.